Pre-exposure prophylaxis or PrEP is the use of an antiretroviral medication to prevent the acquisition of HIV infection by uninfected persons. PrEP may either be taken orally, using an antiretroviral drug available for treatment of HIV infection (tenofovir plus emtricitabine), or topically as a vaginal gel containing tenofovir. The efficacy of oral PrEP has been shown in four randomized control trials and is high when the drug is used as directed. The efficacy of gel has been shown in one trial and is moderate. Making these drugs available for safe, effective prevention outside the clinical trial setting is the current challenge.
Clinical Infectious Diseases supplement on PEP and PrEP
- The strategic use of antiretrovirals to prevent HIV infection: a converging agenda
- Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach
- The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention